TKTX and AVE seek Dynepo approval

Transkaryotic (TKTX) and Aventis (AVE) applied for U.S. and European marketing approval of Dynepo gene activated erythropoietin (GA-EPO) to treat anemia in patients with chronic renal failure. The com...